Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation

International Journal of Cancer

Volumn 90, Issue 2, 2000, Pages 104-109

  Koffman, B H ^a   Kennedy, Andrew S ^a,b   Heyman, M ^a   Colonna, J ^a   Howell, C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Department of Radiation Oncology ^*  (United States)

Author keywords

Biliary obstruction; Liver transplant; Lymphoproliferative disorder; Posttransplant; Radiation

Indexed keywords

ACICLOVIR; CYCLOSPORIN;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ALGORITHMS; CYCLOSPORINE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; PREDNISONE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034073933     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000420)90:2<104::AID-IJC6>3.0.CO;2-0     Document Type: Article

References (41)

1. Murray JE, Wilson RE, Tilney NL, Merrill JP, Cooper WC, Birtch AG, Carpenter CB, Hager EB, Dammin GJ, Harrison JH. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968;168:416-435.
2. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1:106-1 12.
3. Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M, Hardesty RL, Dummer JS. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991;10: 877-886; discussion 886-877.
4. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991;23:1473-1476.
5. Stieber AO, Boillot O, Scotti-Foglieni C, Nalesnik MA, Gordon RD, Marino I, Mazzaferro V, Starzl TE. The surgical implications of the posttransplant lymphoproliferative disorders. Transplant Proc 1991;23:1477-1479.
6. Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, Gonwa TA, Holman M, Klintmalm G. De novo malignancy following liver transplantation: a single-center study. Transplant Proc 1993;25:1397-1399.
7. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of posttransplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
8. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Jr, Hardesty RL, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-587.
9. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86:3333-3340.
10. Swinnen LJ. Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am 1997;11:963-973.
11. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991;70:137-160.
12. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol 1994;5:29-35.
13. Purtilo DT. Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet 1980;1:300-303.
14. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen anti-body responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-984.
15. Shapiro RS, Chauvenet A, McGuire W, Pearson A, Craft AW, McGlave P, Filipovich A. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin [Letter]. N Engl J Med 1988;318:1334.
16. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Gamier JL, Niaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991;324:1451-1456.
17. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, Balfour HH Jr, Simmons RL, Najarian JS. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982;306:913-918.
18. Pirsch JD, Stratta RJ, Sollinger HW, Hafez GR, D'Alessandro AM, Kalayoglu M, Beizer FO. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989;86:241-244.
19. McCarthy M, Ramage J, McNair A, Gane E, Portmann B, Pagliuca A, Rela M, Heaton N, Mufti GJ, Williams R. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol 1997;27:1015-1021.
20. Garrett TJ, Chadburn A, Barr ML, Drusin RE, Chen JM, Schulman LL, Smith CR, Reison DS, Rose EA, Michler RE, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993;72:2782-2785.
21. Gallego-Melcon S, Sanchez de Toledo J, Martinez V, Moraga F, Iglesias J, Ruiz C, Allende E. Non-Hodgkin's lymphoma after liver transplantation: response to chemotherapy. Med Pediatr Oncol 1996;27: 156-159.
22. Swinnen LJ. Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation. Leuk Lymphoma 1997;28:89-101.
23. O'Brien S, Bernert RA, Logan JL, Lien YH. Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J Am Soc Nephrol 1997;8:1483-1489.
24. Leblond V, Sutton L, Dorent R, Davi F, Bitker MO, Gabarre J, Charlotte F, Ghoussoub JJ, Fourcade C, Fischer A, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-968.
25. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation [see comments], N Engl J Med 1994; 330:1185-1191.
26. Tsai DE, Hardy CL, Vaughn DJ, Porter DL, Moore HCF, Schuster SJ, Loh EY, Luger S, Stadtmauer EA. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder (PTLD): analysis of prognostic variables and long term followup of 37 patients. Proc ASCO 1999;14.
27. Sutcliffe SB, Gospodarowicz MK, Bush RS, Brown TC, Chua T, Bean HA, Clark RM, Dembo A, Fitzpatrick PJ, Peters MV. Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol 1985; 4:211-223.
28. Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer 1979;43:1245-1254.
29. Paryani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS. Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II. Cancer 1983;52:2300-2307.
30. Kaminski MS, Coleman CN, Colby TV, Cox RS, Rosenberg SA. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986;104: 747-756.
31. Hoppe RT. The role of radiation therapy in the management of the non-Hodgkin's lymphomas. Cancer 1985;55:2176-2183.
32. Gomez GA, Barcos M, Krishnamsetty RM, Panahon AM, Han T, Henderson ES. Treatment of early - stages I and II - nodular, poorly differentiated lymphocytic lymphoma. Am J Clin Oncol 1986;9:40-44.
33. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470-1480.
34. Gospodarowicz MK, Wasserman TH. Non-Hodgkin's lymphomas. In: Perez CA, Brady LW, editors. Principles and practice of radiation oncology. Philadelphia: Lippincott-Raven; 1998. p 1987-2011.
35. Glick JH, Kim K, Earl J. An ECOG randomized phase III trial of CHOP vs CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1995;14:391 abstract.
36. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339:21-26.
37. Hallahan DE, Farah R, Vokes EE, Bitran JD, Ultmann JE, Golomb HM, Weichselbaum RR. The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone. Im J Radiat Oncol Biol Phys 1989-.17: 767-771.
38. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988;25:367-472.
39. Chen JL, Osborne BM, Butler JJ. Residual fibrous masses in treated Hodgkin's disease. Cancer 1987;60: 407-413.
40. Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985;3:637-640.
41. Stewart FM, Williamson BR, Innes DJ, Hess CE. Residual tumor masses following treatment for advanced histiocytic lymphoma. Diagnostic and therapeutic implications. Cancer 1985;55:620-623.